Lead Product(s): Undisclosed
Therapeutic Area: Gastroenterology
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $1,538.0 million Upfront Cash: $38.0 million
Deal Type: Collaboration April 06, 2020
Second Genome will utilize its proprietary Microbiome Analytics Platform™ to identify novel biomarkers associated with clinical response to Gilead’s investigational medicines.